The VAM meeting VI presents the new evidence in the treatment of cardiovascular diseases.

-the day, organized by Almirall, has gathered in Barcelona more than 300 national and international specialists from the fields of vascular medicine

-the results of the study EMPHASIS show that optimal heart failure therapy reduces mortality by 30% and the hospital readmissions in more of the 40% than the classic treatment

Barcelona, 2012-February 10 and February 11 the VI VAM meeting was held in Barcelona (Vascular Disease: A Multidisciplinary Approach), organized by Almirall, and brought more than 300 national and international specialists from the different areas of cardiovascular medicine in Barcelona.

In this Sixth Edition, an update of cardiovascular pathology was carried out from a multidisciplinary point of view. Addressed issues relating to the treatment of various forms of cardiovascular disease, its relationship with diabetes and other risk factors and, especially, the new evidence which contributed to recent studies on the treatments for heart failure, as well as the antithrombotic in atrial fibrillation.

For the Dr. José Ramón González Juanatey, of the service of Cardiology of the clinical University Hospital Santiago de Compostela and member of the Scientific Committee of the 2012 VAM, the holding of the sixth edition of the VAM demonstrates the consolidation of an encounter, which has positioned itself as a reference point in the multidisciplinary integration of cardiovascular disease in Spainby both the content of the conferences and the topics to be addressed in the workshops and the possibility of immediate clinical application of each one of them ”.

New evidence in the treatment of heart failure

According to the presented study EMPHASIS, right heart failure therapy allows to obtain a reduction of mortality and contributes to the stabilization of patients with heart failure (CI). The optimal treatment of this pathology influences positively in terms of quality of life, improving the symptoms and the successive events, which affects in turn to a reduction in the costs of treatment of this type of patient.

For the internist, Dr. Pedro Conthe, of the Hospital General Universitario Gregorio Marañón in Madrid and member of the Scientific Committee of the 2012 VAM, study EMPHASIS, one of the most important in recent years, has shown that the optimal treatment of this pathology allows a reduction in mortality in an additional 30% which is obtained with clá therapySICA and helps to reduce by more than 40% of hospital readmissions for heart failure ”.

These are some of the results presented, during this last weekend in Barcelona, from the Dr. Bertram Pitt of the school of Medicine of the University of Michigan, one of the most prestigious international specialists in this field and one of the principal investigators of this study.

New DPP-4 inhibitors have five years experience in clinical practice and constitute an effective treatment in the control of patients with type 2 diabetes, in combination with metformin. Presented data show its security from the point of view of vascular, is accompanied by a reduction in the progression of cardiovascular and renal disease in diabetic.

Has also stressed the need for comprehensive management of the disease in the diabetic patient: tension, cholesterol levels, habits of life and food, etc., the presentation by Dr. Eberhard F.Muell of the Munich Diabetes Research Institute, concluded with an analysis of future prospects and research being undertaken in This type of treatment.

The Mva, a multidisciplinary before cardiovascular disease reference

Dr. González Juanatey has presented the new guidelines in the approach to this disease, as well as combinations of molecules that have been most effective in the clinical activity antihypertensive. Currently, more than 70% of hypertensive patients need a combination therapy for a proper control of their disease.

Finally, the Dr. José Luis López Sendón, of the Hospital de la Paz, has highlighted the influence of the different antithrombotic in the treatment of atrial fibrillation, analyzing the pros and cons with the various therapeutic options in this field. This review has coincided with the recent announcement of the agreement to co – Spain promoting the oral anticoagulant Xarelto ® (rivaroxaban) between Bayer and Almirall.

Virtual meeting and workshops of clinical application

The program has been completed with practical workshops which discussed various topics of the cardiovascular pathology. For Dr. Javier Díez, of the service of Nephrology of the Clínica Universitaria de Navarra and member of the Scientific Committee of the VAM, the theoretical approach of the Mva helps specialists address the hottest issues of the cardiovascular pathology from a clinical point of view. This year the workshops have dealt patient with atrial fibrillation and the complications posed by, the efficacy and safety of the treatments of the diabetic patient without adequate metabolic control or the increase in the incidence of hypertension resistant to therapy ”, adds Dr. Díez.

The therapeutic areas in which concentrates its resources in research are related to the treatment of asthma, COPD (chronic obstructive pulmonary disease), gastrointestinal disorders, psoriasis and other skin disorders.

Currently, Almirall products are present in more than 70 countries, with direct presence in Europe and Latin America through 12 subsidiaries.